What this framework is
Hainan Free Trade Port island-wide special customs operations began on 18 December 2025. This is a current-status point about the customs framework. It should not be described as a future 2025 milestone.
Who may find it relevant
Overseas healthcare companies considering a Hainan workstream may need to understand how the customs framework interacts with their supply, import, operating, and project assumptions. That assessment should begin with the specific product, transaction, entity, and activity rather than a broad policy slogan.
What it does not provide
The customs framework does not determine clinical access, Mainland marketing authorization, or drug and medical-device zero-tariff eligibility. It does not establish that a product qualifies for Lecheng use, national registration, reimbursement, procurement, or a particular tax or customs treatment.
Questions to assess
- Which entity, product, transaction, and movement of goods are being considered?
- Which current customs, tax, import, regulatory, and healthcare rules apply separately?
- Is a product-specific clinical or registration pathway relevant, and under which official procedure?
- What qualified customs, tax, legal, regulatory, or clinical advice is required?
- Which assumptions are supported by current official text, and which still require confirmation?